A Breakthrough in Sleep Medicine: FDA Approves First Drug to Treat ONE of the Underlying Cause of Narcolepsy Type 1

Board-certified neurologist and sleep specialist Dr. Anne Marie Morse breaks down the FDA's landmark approval of Takeda's ORZEYFUL — the first medicine to treat the root cause of narcolepsy type 1, not just its symptoms.

Sleep medicine has taken a historic step forward. On August 5, 2026, the U.S. Food and Drug Administration approved ORZEYFUL™ (oveporexton), a first-in-class oral orexin receptor agonist developed by Takeda Pharmaceuticals for the treatment of narcolepsy type 1 (NT1) in adults.

This is not just another medication added to the shelf. This is the first and only FDA-approved medicine to treat at the level of orexin dysfunction, and for some living with narcolepsy type 1 — orexin deficiency can be the cause. For those living with CSF orexin deficient narcolepsy this offers more than treating individual symptoms as they appear. As a neurologist and sleep medicine specialist, I want to explain why this matters, what it means for patients, and why the entire field of sleep medicine should be paying close attention.

What Is Narcolepsy Type 1?

Narcolepsy type 1 is a rare, chronic neurological disease that affects an estimated 120,000-200,000 people in the United States. One of the causes that have been identified is a reduction to absence of orexin in the cerebrospinal fluid, which may be due to a loss of orexin-producing neurons or possibly a silencing of the expression of orexin in these neurons in the brain — specifically in the lateral hypothalamus. Orexin (also called hypocretin) is a neuropeptide that has 2 forms Orexin A and B and they act on both orexin 1 and orexin 2 receptors. In terms of sleep it is one of the drivers for regulating wakefulness, sleep-wake stability, and muscle tone control during waking hours (and during REM sleep). The function of orexin signaling extends beyond sleep and has non-sleep related impact across really almost every organ system and function in our body. 

When orexin is reduced or unavailable the brain loses the sharp boundary between sleep and wakefulness. This is a result of the system that is left to function with an inappropriate amount of a critical team player in the game of life, and other members of the CNS crew are either left unopposed like melanin concentrating hormone (MCH), needing to do more work potentially like glutamate or the endocannabinoid, and some with no idea when they are supposed to show like our monoamines and catecholamines. What’s left? Symptoms of narcolepsy!

 People with NT1 experience:

• Excessive daytime sleepiness — an overwhelming, physiological drive to sleep during waking hours. This is not tiredness. This is not fatigue. This is the brain actively and repeatedly attempting to transition into sleep throughout the day, regardless of how much nighttime sleep the person has had.

• Cataplexy — sudden, transient episodes of muscle weakness triggered by strong emotions like laughter, surprise, or anger. These episodes can range from a slight drooping of the eyelids to complete postural collapse.

• Disrupted nighttime sleep — fragmented, poor-quality sleep with frequent awakenings, vivid dreams, and sleep paralysis. The irony of NT1 is that while patients fight overwhelming sleepiness during the day, they often cannot achieve high quality, consolidated, restorative sleep at night.

• Other REM dissociative features – Sleep paralysis, a temporary feeling of being frozen or stuck while falling asleep or waking up, sleep related hallucinations, vivid dream like content that is hard to distinguish if they are real or dreams, and for many nightmare disorder and some REM behavior disorder. 

This is a 24-hour disease. It does not clock out at night. And until today, every available treatment has been for symptoms not one of the identified pathophysiologic causes. It’s important to recognize that not all people with NT1 have a deficiency or absence of orexin and this only reflects a knowledge gap about all the causes, not a diagnostic error or invalidation of one’s lived experience.

The Opportunity With How We Treat NT1

To understand why ORZEYFUL is a paradigm shift, you need to understand some of the limitations of current treatments.

Like many neurologic conditions, until now, NT1 has been managed symptomatically. This isn’t a bad thing. We have had a growing number of incredible treatments that have dramatically improved the lives of many living with NT1. The plethora of options that exist have allowed for increasing individualization of care based on the burden experience, with stimulants or wake-promoting agents for daytime sleepiness, pitolisant for wake promotion and cataplexy, antidepressants off label for cataplexy and sometimes doing double duty for mental health. And the oxybate family of medications that until now have probably been the most effective long term strategy for managing multiple symptoms of narcolepsy, like EDS, cataplexy, DNS and REM dissociative symptoms, even though only technically approved for EDS and cataplexy. 

Each of these treatments targets part of disease expression and frequently require polytherapy. None are known to act on the orexin receptors or system itself. And again, this is where some living with narcolepsy are at a loss. As a clinician, I have sat with patients who are doing "everything right" — taking their medications, practicing good sleep hygiene, napping strategically — and still fighting to stay awake at their child's school play, or while hanging out with friends. As with any current standard of care we are always looking for more options to treat more patient more optimally. And when we can get at the cause it is an opportunity to treat more completely.

What Makes ORZEYFUL Different

A drug named for orexin and joyful, and many have rejoiced at this new option becoming approved. ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R) agonist. Let me translate that into plain language.

Orexin normally acts on two receptors in the brain: OX1R and OX2R. In narcolepsy type 1, the neurons that produce orexin are destroyed — likely by an autoimmune process — so the brain is starved of the orexin it needs to sustain wakefulness and regulate sleep-wake transitions.

ORZEYFUL does not replace orexin itself. Instead, it directly stimulates the OX2 receptor, mimicking the effect that orexin would normally have. It essentially tells the brain's wakefulness circuitry, "You still have a receptor that works — let me activate it." This restores signaling through the pathway that was lost, rather than treating downstream symptoms through unrelated mechanisms.

This is what we mean when we say it treats the underlying cause. It does not bring back the orexin-producing neurons. But it restores the signaling those neurons used to provide, through the same receptor pathway the brain was built to use.

What the Clinical Trials Showed

The FDA approval is based on a comprehensive Phase 3 program that included two global studies: FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002).

The results were statistically significant across the full range of NT1 symptoms. Patients taking ORZEYFUL showed meaningful improvements compared to placebo in:

• Excessive daytime sleepiness (measured by standardized sleepiness scales and maintenance of wakefulness tests)

• Cataplexy frequency

• Health-related quality of life

• Cognitive function

• Nighttime sleep quality

ORZEYFUL was generally well-tolerated in clinical studies. The most common side effects included insomnia (trouble sleeping), urinary urgency and frequency, and excessive saliva. These side effects are consistent with the drug's mechanism of action — orexin receptors are involved in multiple physiological systems, including bladder function and arousal regulation.

It is worth noting that insomnia as a side effect in a narcolepsy drug may seem counterintuitive, but it reflects the precision of the mechanism: by promoting wakefulness through orexin signaling, the drug can overshoot in some patients, particularly at treatment initiation. This is a manageable clinical issue, not a reason for alarm.

Why This Matters Beyond Narcolepsy

The approval of ORZEYFUL is a watershed moment for narcolepsy type 1, but its implications extend further.

Orexin is emerging as one of the most promising therapeutic pathways in all of neuroscience. The same orexin system that is disrupted in NT1 is being investigated as a target for narcolepsy type 2, idiopathic hypersomnia, and a range of other sleep-wake disorders, neurologic conditions and psychiatric diagnoses. Takeda is already advancing orexin agonists in broader indications, and other pharmaceutical companies — including Eli Lilly with the acquisition of Centessa— are developing competing orexin therapies. The race has been fast and furious, and on the horizon we will see others, like Alkermes, who is likely to be the next to the finish line.

For the first time, we have proof that we can treat a sleep disorder by addressing its molecular root cause rather than suppressing its symptoms. This is the template for the next generation of sleep medicine.

What Patients Should Know

If you or someone you love has narcolepsy type 1, here is what you need to know right now:

ORZEYFUL is not yet available at your pharmacy. Because it is classified as a controlled substance, it must go through DEA scheduling — a process that is expected to take up to 90 days. Once that process is complete, the medication will be available through a specialty pharmacy.

This is a treatment specifically approved for narcolepsy type 1 (narcolepsy with cataplexy) in adults. It is not approved for narcolepsy type 2, idiopathic hypersomnia, or other sleep disorders at this time — though research is actively underway.

This approval also does not mean current therapies available become less important or valuable. These will still be needed not only for patients living with narcolepsy, but a broader community of people living with sleep disorders and other brain health conditions. 

If you are currently taking medications for NT1, do not stop or change anything on your own, especially if they are helping you. Talk to your sleep specialist about whether ORZEYFUL may be appropriate for your treatment plan once it becomes available. Every patient's clinical picture is different, and medication decisions should always be made collaboratively with your physician.

The Bigger Picture: Sleep Medicine Is Advancing

As someone who has dedicated my career to neurology and sleep medicine, days like today are why I do this work. For too long, sleep disorders have been misunderstood, stigmatized, and underfunded relative to their impact on public health. Narcolepsy type 1 is a perfect example — a devastating neurological disease that has been dismissed by many as "just being sleepy" when it is, in fact, a profound disruption of the brain's most fundamental regulatory system.

ORZEYFUL proves something I have been saying for years: sleep is not optional, sleep disorders are not trivial, and the science of sleep deserves the same investment and innovation as any other area of medicine.

This is a win for the up to 200,000 Americans living with narcolepsy type 1. It is a win for the researchers and clinicians who have spent decades studying the orexin system. And it is a reminder to all of us that sleep advocacy is not just about wearing the message — it is about demanding that sleep science gets the attention, funding, and respect it deserves.

Take the nap. Take the meds. Take the science seriously.

Because DAMM good sleep is not a luxury. It is a medical necessity — and today, medicine just took a massive step forward in delivering it.

Dr. Anne Marie Morse, DO, is a board-certified neurologist and sleep medicine specialist, and the founder of DAMM Good Sleep — a sleep advocacy brand on a mission to challenge hustle culture and champion the science of sleep. Learn more at dammgoodsleep.myshopify.com.